A Multi-Center, Randomized Evaluation of Treatment Outcomes in Patients with De Novo Coronary Atherosclerotic Lesions Treated with the Conor Sirolimus-eluting Coronary Stent System compared to the TAXUS Liberte Paclitaxel-eluting Coronary System Assessed by Angiographic Late Loss at Six Months .

Trial Profile

A Multi-Center, Randomized Evaluation of Treatment Outcomes in Patients with De Novo Coronary Atherosclerotic Lesions Treated with the Conor Sirolimus-eluting Coronary Stent System compared to the TAXUS Liberte Paclitaxel-eluting Coronary System Assessed by Angiographic Late Loss at Six Months .

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Paclitaxel; Sirolimus
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Registrational; Therapeutic Use
  • Acronyms NEVO-RES-I; RES-ELUTION
  • Sponsors Conor Medsystems; Cordis Corporation
  • Most Recent Events

    • 21 Sep 2010 Results presented at the 22nd Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics.
    • 25 May 2010 Twelve-month results were presented at EuroPCR 2010, according to a Cordis Corporation media relese.
    • 26 Sep 2009 Interim results for an intravascular ultrasound substudy have been presented at the 21st Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top